PharmaMar First Nine Months 2026 Net Income Falls 43% to €8.7 Million

• PharmaMar’s net income fell 43% year over year to €8.7 million in the first nine months of 2026.
• Revenue rose 12% year over year to €146.9 million.
• Lower income from the Merck licensing agreement and reduced Sylentis grant recognition weighed on profit.
• Zepzelca’s European commercial rollout began July 1 in Germany and Austria for first-line maintenance treatment of small-cell lung cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pharma Mar SA published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.